ImClone Systems Incorporated (NASDAQ: IMCL) and UCB have entered into a worldwide strategic partnership for the development and commercialization of CDP-791, a novel, investigational antibody targeting the vascular endothelial growth factor receptor-2 (VEGFR-2) that is currently being developed by UCB.
one of New Jersey's fastest growing general contracting firms, has recently completed a high-end renovation project on behalf of
ImClone Systems Incorporated at 33 Chubb Way in Branchburg, N.
Company analysis includes a history of
ImClone Systems, a business segment analysis of the segments
ImClone Systems operates through, a look at the organization structure of the company, a geographical operating segments analysis, an analysis of the company's major competitors.
NEW YORK --
ImClone Systems Incorporated (NASDAQ: IMCL) announced today that the Company is scheduled to present at the Goldman Sachs 28th Annual Global Health Care Conference in Dana Point, CA on June 13, 2007 from 3:20 PM to 3:50 PM Pacific Time (6:20 PM to 6:50 PM Eastern Time).
NEW YORK --
ImClone Systems Incorporated (NASDAQ: IMCL) announced that the Company is scheduled to present at the Bear Stearns 3rd Annual Biotech Confab in Boston, MA on June 7, 2007 from 4:50 PM to 5:15 PM Eastern Time.
NEW YORK --
ImClone Systems Incorporated (NASDAQ: IMCL) announced today that the Company is scheduled to present at the Citigroup 2007 Healthcare Conference in New York, NY on Thursday, May 24, 2007 from 12:00 PM to 12:25 PM Eastern Time.
NEW YORK --
ImClone Systems Incorporated (NASDAQ: IMCL) announced that the Company is scheduled to present at the Morgan Stanley Global Healthcare Unplugged Conference from 11:00 AM to 11:40 AM Eastern Time today.
NEW YORK --
ImClone Systems Incorporated (NASDAQ: IMCL) announced today that the Company is scheduled to present at The Lehman Brothers 10th Annual Global Healthcare Conference in Miami, Florida on Wednesday, March 21, 2007 from 10:45 AM to 11:10 AM Eastern Time.
NEW YORK --
ImClone Systems Incorporated (NASDAQ: IMCL) announced today that the Company is scheduled to present at The Cowen and Company Twenty Seventh Annual Health Care Conference on Tuesday, March 13, 2007 from 8:00 AM to 8:35 AM Eastern Time.
NEW YORK --
ImClone Systems Incorporated (NASDAQ: IMCL) announced today that it has opted-out of its development agreement with UCB S.
NEW YORK --
ImClone Systems Incorporated (NASDAQ: IMCL) announced today that the Company is scheduled to present at The Merrill Lynch Eighteenth Annual Global Pharmaceutical, Biotechnology and Medial Device Conference on Tuesday, February 6, 2007 from 2:20 PM to 3:00 PM Eastern Time.
NEW YORK --
ImClone Systems Incorporated (NASDAQ: IMCL) today announced that it expects to disclose the result of a Phase III study of ERBITUX([R]) (cetuximab) plus FOLFIRI (an irinotecan-based chemotherapy) in patients with previously untreated metastatic colorectal cancer, before the end of the week of January 8, 2007.
